li001

Blocking p300 Protein Restores Chemotherapy Sensitivity in Resistant Cancers

Researchers have identified a new way to overcome chemotherapy resistance by targeting a protein called p300. Their study, published in Genes & Development, shows that blocking p300 pushes cancer cells into a fatal state of internal stress. Normally, when chemotherapy damages a cell’s DNA, p300 helps pause the cell’s activity so the damage can be […]

Blocking p300 Protein Restores Chemotherapy Sensitivity in Resistant Cancers Read More »

FDA Accepts Ameluz Application as First Potential Photodynamic Therapy for Superficial Basal Cell Carcinoma

The FDA has accepted Biofrontera’s application to expand the use of Ameluz (aminolevulinic acid) topical gel, used with the RhodoLED red light device, to treat superficial basal cell carcinoma (BCC). The agency found no problems with the filing and set a decision date of September 28, 2026. If approved, Ameluz would become the first photodynamic

FDA Accepts Ameluz Application as First Potential Photodynamic Therapy for Superficial Basal Cell Carcinoma Read More »

AI Tool Uses CT Scans to Predict Survival Risk in Oropharyngeal Cancer Patients

Researchers have developed and validated an AI-based deep learning system to better predict outcomes in patients with oropharyngeal cancer (OPC) using CT scans taken before treatment. The tool focuses on extranodal extension (ENE), a condition in which cancer spreads outside the lymph node. ENE is usually confirmed only after surgery, but this new AI model

AI Tool Uses CT Scans to Predict Survival Risk in Oropharyngeal Cancer Patients Read More »

Chemotherapy Before Surgery Improves Survival in Early Pancreatic Cancer

A new clinic study found that giving chemotherapy before surgery can significantly improve survival for patients with early-stage pancreatic cancer, especially when the tumor is touching nearby blood vessels. In the past, many patients had surgery first. But researchers analyzed data from about 1,400 patients and found an important difference. When tumors were touching a nearby

Chemotherapy Before Surgery Improves Survival in Early Pancreatic Cancer Read More »

FDA Approves Keytruda for PD-L1–Positive Platinum-Resistant Ovarian Cancer

The FDA has approved pembrolizumab (Keytruda) and its subcutaneous version, Keytruda Qlex, for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The approval is for patients whose tumors test positive for PD-L1 (Combined Positive Score of 1 or higher) and who have already received one or two prior treatment regimens. The decision is

FDA Approves Keytruda for PD-L1–Positive Platinum-Resistant Ovarian Cancer Read More »

Immune Cells Found to Fuel Tumor Growth Through CCL3 Signal

Researchers have discovered how the body’s own immune system can unintentionally help cancer grow. Neutrophils are white blood cells that normally fight infection. But the study shows that tumors can “reprogram” these cells. Instead of attacking cancer, the altered neutrophils begin producing a molecule called CCL3. This molecule acts like a growth signal, helping tumors

Immune Cells Found to Fuel Tumor Growth Through CCL3 Signal Read More »

Ovarian Cancer Found to Hijack Healthy Cells to Speed Deadly Spread

A new study explains why ovarian cancer spreads so quickly and becomes so dangerous. Researchers found that cancer cells do not spread alone. Instead, they recruit healthy cells in the abdomen to help them invade other organs. Unlike many cancers that travel through the bloodstream, ovarian cancer cells float in abdominal fluid. During this time,

Ovarian Cancer Found to Hijack Healthy Cells to Speed Deadly Spread Read More »

Study Shows Strong Results for Keytruda Combination Before Surgery in Head and Neck Cancer

A phase 2 study found that combining pembrolizumab (Keytruda) with docetaxel and cisplatin before surgery works very well for patients with locally advanced head and neck squamous cell carcinoma that can still be removed. In the study of 49 patients, 87.8% responded to treatment. Among those who had surgery, 44.4% had no remaining cancer found

Study Shows Strong Results for Keytruda Combination Before Surgery in Head and Neck Cancer Read More »

EI24 Gene Shows Dual Role in Cancer, Emerging as Promising Diagnostic and Therapeutic Target

New research highlights the complex role of the EI24 gene in cancer, showing that it can act either as a tumor suppressor or, in some cases, support tumor growth. EI24 is activated by the p53 tumor suppressor when DNA is damaged and plays a key role in autophagy and programmed cell death—two processes that help

EI24 Gene Shows Dual Role in Cancer, Emerging as Promising Diagnostic and Therapeutic Target Read More »